Companies Lisata Therapeutics, Inc
Lisata Therapeutics (LSTA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Lisata Therapeutics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,691,174FY2024
- $1,147,359FY2025
CEO total pay was $1,147,359 in fiscal 2025, down from $1,691,174 in fiscal 2024.
FY2025: salary $711,729 · bonus $0 · stock awards $307,800 · option awards $104,080
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Mazzo | $711,729 | $0 | $307,800 | $104,080 | $0 | $0 | $23,750 | $1,147,359 |
| Chief Executive Officer | ||||||||
| Kristen Buck | 599,342 | 0 | 95,000 | 33,826 | 0 | 0 | 8,250 | 736,418 |
| Former Executive Vice President R&D and Chief Medical Officer | ||||||||
| James Nisco | 350,000 | 0 | 57,000 | 18,214 | 0 | 0 | 8,250 | 433,464 |
| Senior Vice President, Finance and Treasury and Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Mazzo | $1,147,359 | $1,691,174 | — | ↓ −543,815 |
| Kristen Buck | 736,418 | 1,065,061 | — | ↓ −328,643 |
| James Nisco | 433,464 | 516,166 | — | ↓ −82,702 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee determines executive compensation based on performance for the respective year, with annual bonuses (short-term incentives) and equity-based compensation (options, restricted stock, and performance-based stock units) designed to align executive interests with stockholders. The company utilizes a peer group benchmarked by Radford/AON to ensure competitive compensation levels within the life science industry.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford/AON |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Nisco | Option | 750 | 3 | — |
| James Nisco | RSU | 1,374 | — | 2,556 |
| James Nisco | Option | 2,000 | 3.08 | — |
| Kristen Buck | Option | 2,250 | 3 | — |
| James Nisco | RSU | 4,000 | — | 7,440 |
| Kristen Buck | RSU | 4,500 | — | 8,370 |
| James Nisco | Option | 5,250 | 3.8 | — |
| Kristen Buck | Option | 7,000 | 3.08 | — |
| David Mazzo | Option | 7,500 | 3 | — |
| Kristen Buck | Option | 9,750 | 3.8 | — |
| James Nisco | RSU | 11,250 | — | 20,925 |
| Kristen Buck | RSU | 13,500 | — | 25,110 |
| David Mazzo | RSU | 15,000 | — | 27,900 |
| Kristen Buck | RSU | 18,750 | — | 34,875 |
| David Mazzo | Option | 23,500 | 3.08 | — |
| David Mazzo | Option | 30,000 | 3.8 | — |
| David Mazzo | RSU | 47,000 | — | 87,420 |
| David Mazzo | RSU | 60,750 | — | 112,995 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gregory B. Brown, M.DIndependent · Board Chair · Compensation · Science and Technology | $94,500 | $60,000 | — | — | — | $154,500 |
| Heidi HensonIndependent · Audit (Chair) · Compensation | 64,000 | 60,000 | — | — | — | 124,000 |
| Steven M. Klosk, J.DIndependent · Audit · Compensation (Chair) | 60,000 | 60,000 | — | — | — | 120,000 |
| Mohammad Azab, M.D., M.B.AIndependent · Science and Technology (Chair) | 53,500 | 60,000 | — | — | — | 113,500 |
| Cynthia L. Flowers, M.B.AIndependent · Audit | 52,500 | 60,000 | — | — | — | 112,500 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $60,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,000 / 12,000 / 9,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $324,500 |
| Equity awards (grant-date value) | $300,000 |
| All other compensation | $0 |
| Total cost of the board | $624,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Lisata Therapeutics as a peer
Companies that benchmark against LSTA
- Passage BIO, Inc.PASGFY2025
Each company listed discloses LSTA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Lisata Therapeutics, Inc | 2025 | David Mazzo | $711,729 | $307,800 | $104,080 | $0 | $1,147,359 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (11 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Mazzo. DEF 14A, filed 2026-10-19. Section “Executive Compensation”. As printed: 1,147,359. View filing ↗
- Section 01, Kristen Buck. DEF 14A, filed 2026-10-19. Section “Executive Compensation”. As printed: 736,418. View filing ↗
- Section 01, James Nisco. DEF 14A, filed 2026-10-19. Section “Executive Compensation”. As printed: 433,464. View filing ↗
- Section 08, Gregory B. Brown, M.D. DEF 14A, filed 2026-10-19. Section “Director Compensation”. As printed: 154,500. View filing ↗
- Section 08, Heidi Henson. DEF 14A, filed 2026-10-19. Section “Director Compensation”. As printed: 124,000. View filing ↗
- Section 08, Steven M. Klosk, J.D. DEF 14A, filed 2026-10-19. Section “Director Compensation”. As printed: 120,000. View filing ↗
- Section 08, Mohammad Azab, M.D., M.B.A. DEF 14A, filed 2026-10-19. Section “Director Compensation”. As printed: 113,500. View filing ↗
- Section 08, Cynthia L. Flowers, M.B.A. DEF 14A, filed 2026-10-19. Section “Director Compensation”. As printed: 112,500. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 324,500 + equity 300,000 + all other 0 = 624,500, summed across the director compensation table rows.
- Lisata Therapeutics, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-10-19. CEO total compensation as printed in Lisata Therapeutics, Inc's own proxy. As printed: 1,147,359. View filing ↗